secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2022-12-23T23:59:59+00:00
Accession:  0001493152-22-036510
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa extends waiver of $1.5M milestone payments due to L&F Research to March 31, 2023
--------------------------------------------------------------------------------

- Second Amendment to Waiver extends L&F Research's forbearance on terminating license for non-payment of $500K IND Milestone and two $500K Phase 1/2 milestone payments.
- Waiver Period extended to March 31, 2023; original deadline was January 3, 2023.
- If license is terminated for other reasons or a bankruptcy event occurs before July 31, 2023, the waiver is void and payment obligations retroactively reinstated.
- All other terms of the underlying License Agreement remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315222036510/0001493152-22-036510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315222036510/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-036510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer